Ampersand Capital Partners

Ampersand is a middle market private equity firm focused on investments in two core sectors: Healthcare and Industrial.

1 review
Add your review

Independent rating of Ampersand Capital Partners VC fund

Overall rating:
1 review
Team quality
Not reviewed
Professionalism
None
Personal qualities
None
Integrity
None
Respect and decency
None
Experience
None
Relevant expertise
None
Investment process
Not reviewed
Approachability
None
Clarity of the process
None
Speed of the process
None
Responsiveness
None
Ease of the process
None
Due diligence
None
Value add
Not reviewed
Supportiveness
None
Value add beyond financing
None
Board activity
None
Terms
None
Founder friendly
None
Help with follow-up rounds
None

About Ampersand Capital Partners VC fund

Website:
http://www.ampersandcapital.com
Founded:
1988
Number of funds:
3
Number of investments:
61
Number of exits:
28
Headquarters:
Wellesley, United States
Organization type:
Private Equity Firm

How Ampersand Capital Partners VC fund invests

Rounds:
Private Equity Round, Venture Round, Series B
Average ticket size:
23.4M USD
Biggest investment:
23.4M USD
Would lead round:
Yes
Would coinvest:
Yes
Countries where invested:
United States, Germany
Sectors of interest:
Biotechnology, Manufacturing, Health Care, Software, Life Science, Therapeutics, Telecommunications, Pharmaceutical, Medical Device, Medical, Information Technology, Genetics, Biopharma

Portfolio - latest investments by Ampersand Capital Partners VC fund
Magritek Ltd
Canopy Biosciences
New England Peptide
Brammer Bio
N2 Biomedical LLC
Genome Diagnostics (GenDx)
vivitide
Avista Pharma
Arranta Bio

Founders' reviews of Ampersand Capital Partners VC fund

Not reviewed
Team quality
Not reviewed
Investment process
Not reviewed
Value add
Not reviewed
Older than a year by non-portfolio founder
Peter Glick: Good New Partner, Not Yet Listed
Peter Glick is an experienced entrepreneur with some unusual domain experience for local VC's. He's also a gem. Smart, approachable and able to align his interests with the entrepreneur. I look forward to seeing him in action at Ampersand, and would consider pitching their fund now that he's on board. His core expertise is in Chemicals and Chemical processing as well as some Biotech. Very smart and strategic, and his own history has shown he can execute.
Similar funds